Call for Papers

Radionuclide Therapy with Alpha-emitting Radiopharmaceuticals

It is our great pleasure to invite you to submit an article or review for a high-profile
multi-journal Special Issue published in:
Applied Radiation and Isotopes(ARI), Nuclear Medicine and Biology (NMB) and Physics Open (PHYSO) with the title: “Radionuclide Therapy with Alpha-emitting Radiopharmaceuticals”.

 

Aims and Scope

This special issue aims to capture the current excitement surrounding recent advances in radionuclide therapy afforded by the high linear energy transfer characteristic of alpha-emitters. By combining the traditional scopes of Applied Radiation and Isotopes(ARI), Nuclear Medicine and Biology (NMB) and Physics Open (PHYSO), this issue welcomes contributions describing all aspects of alpha therapy, from radionuclide production to patient treatment. New approaches to production and harvesting of radionuclides are making more alpha-emitters available in useful quantities, fueling research in radiopharmaceutical chemistry, in vitro and in vivo evaluation of new radiopharmaceuticals, targeted therapy, precision and personalized dosimetry, and theranostics. These efforts are supported by the availability of new measurement standards and improved nuclear decay data. ARI, NMB, and PHYSO are proud to team up to address this important topic, integrating cross-disciplinary innovations to highlight the role of alpha-emitters in the bright future of therapeutic nuclear medicine.

Topics of Interest

Any contribution that provides an added value to the development and practice of alpha emitter-based radiotherapy is of interest to this special issue. The topics of interest include – but are not limited to– the following:

Radiation Safety Detection Activity Standards Quality control Radionuclide Production Separations and Impurities radiopharmaceutical Chemistry in vitro evaluation: binding, stability, cellular assays in vivo evaluation,: biodistribution, metabolic stability Theranostic applications Dosimetry

Papers will receive maximum visibility as they are published in a regular issue of your chosen journal and will also appear as part of the article collection on all three ScienceDirect webpages.

 

Guest Editors

Dr. Denis Bergeron, National Institute of Standards and Technology, Radiation Physics Division, Gaithersburg, Maryland, United States of America

Professor Albert Windhorst, VU University Medical Center, Department of Radiology and Nuclear Medicine, Amsterdam, Netherlands

Open Access option

The publication of this special issue in the journals ARI and NMB follows the subscription model (no open access), all articles published in PHYSO are Open Access publications.

If you prefer to publish your contribution Open Access, please submit your study directly to PHYSO and we are happy to announce that for all PHYSO articles in this special issue, your OA fee will be waived!

 

Submission Deadline: October 1, 2021

 

Manuscript Preparation

Depending on the scope of your article we would like to encourage you to choose one of the journals (ARI, NMB or PHYSO) for submitting of your manuscript. Please find below some information about the aims &scope of the three journals.

The general format for submission of papers can be found on the journal’s Guide for authors website at:

ARI https://www.elsevier.com/journals/applied-radiation-and-isotopes/0969-8043/guide-for-authors

NMB https://www.elsevier.com/journals/nuclear-medicine-and-biology/0969-8051/guide-for-authors

PHYSO https://www.elsevier.com/journals/physics-open/2666-0326/guide-for-authors

Submission websites:
To ensure that all manuscripts are correctly identified for inclusion into the special issue, authors must select “VSI: alpha emitters” when they reach the “Article Type” step in the submission process. Submitted papers must be written in English and should include full affiliation postal addresses for all authors.

ARI https://www.editorialmanager.com/ari/default.aspx

NMB https://www.editorialmanager.com/nucmedbio/default.aspx

PHYSO https://www.editorialmanager.com/physo/default.aspx

Only full-length papers and review articles will be considered for publication, subject to peer review by a minimum of two reviewers. There are no page limits although the length of the paper should be appropriate for the material being presented.

While the deadline for submissions is 1 October 2021, papers will be published electronically as soon as they are accepted. The printed issue of ARI and NMB will be assembled within a reasonable time with late papers being printed in regular issues of your chosen journal. We will compile all special issue articles online as virtual special issue, making your article visible on all three ScienceDirect websites. This article collection will contain all accepted articles from all three journals. All articles will be typeset at no cost to the author; there is a charge for printing color figures although there is no charge for color figures on the electronic version.

If the editors have the impression your submitted manuscript is better suited for one of the other journals, they maintain the freedom to transfer your manuscript.

Aims & Scope of the participating journals

Applied Radiation and Isotopes(ARI)provides a high quality medium for the publication of substantial, original and scientific and technological papers on the development and peaceful application of nuclear, radiation and radionuclide techniques in chemistry, physics, biochemistry, biology, medicine, security, engineering and in the earth, planetary and environmental sciences, all including dosimetry. Nuclear techniques are defined in the broadest sense and both experimental and theoretical papers are welcome. They include the development and use of α- and β-particles, X-rays and γ-rays, neutrons and other nuclear particles and radiations from all sources, including radionuclides, synchrotron sources, cyclotrons and reactors and from the natural environment.

Relevant topics for Applied Radiation and Isotopes include the following:

· Radiation Sources: design, construction, production, characteristics.

· Radionuclides: production, activation cross-sections, target design, processing, quality control procedures.

· Synthesis of Labelled Compounds: synthesis, purification, quality control, in vitro testing of radionuclide-labelled compounds/ radiopharmaceuticals.

· Measurement of Radiation and Radioactivity: measurement of X-rays, γ-rays, α- and β-particles and other forms of radiation; nuclear instrumentation, including radiation spectrometry, dosimetry, novel counting systems and whole-body counters, novel radiation detector systems.

· Radioanalytical Methods: activation analysis, isotope dilution analysis, radioimmunoassay, radionuclide tomography, radiation spectrometry.

· Nuclear Physics and Chemistry topics including data compilations, directly relevant to practical applications.

· Nuclear Magnetic Resonance/Electron Spin Resonance: dosimetry, dating, imaging, biomedical applications and radiation accidents.

· Medical Radiation: the development of applications of ionising radiation and radioisotopes in radiation therapy, imaging and nuclear medicine.

· Accelerator Mass Spectrometry: methodology, biomedical, environmental and other applications.

· Nuclear Geophysics: studies of the earth's crust, the hydrosphere, the atmosphere and planetary bodies; nuclear methods for exploration, extraction, transport and use of water, oil, gas, coal and other minerals.

· Radiochemistry: chemical behaviour and speciation of radionuclides.

· Environment: chemical behaviour and speciation of radionuclides and labelled compounds other than those of direct clinical interest, in geological, environmental, human, animal or plant systems; factors which modify this behaviour.

Nuclear Medicine and Biology (NMB) publishes original research addressing all aspects of radiopharmaceutical science: synthesis (automated and manual),in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radio pharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration.

These multidisciplinary studies should validate the mechanism of localization whether the tracer is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the tracer to changes in disease or treatment, although studies validating mechanism alone are acceptable as well.

If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized and should provide a substantial improvement over existing methodologies.

Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radio­pharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.

Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.

Physics Open (PHYSO), a gold open access, peer-reviewed journal that seeks full research articles in all areas of physics and related interdisciplinary areas, be it fundamental or applied. The journal will cover theoretical, computational as well as experimental research.

The Board of Editors consists of a selection of editors from the Elsevier physics journal suite. The Board is committed to extending the high standards of excellence of their respective journals to this new journal.

Publishing in Physics Open allows authors to publish gold OA, while benefitting from the knowledge of experienced Editors and their partner journals at the same time.